May 12th 2024
Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Study Illuminates Role of AR-V7 in Carcinogenesis
May 21st 2015The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association Meeting by Tyler M. Bauman, BS, is bringing the discussion into focus.
Read More
Long-Term Exposure to Low-Dose Prednisone With Abiraterone Acetate for mCRPC
May 21st 2015Leonard Gomella, MD, professor, Jefferson University, physician, chair, Department of Urology, director, Kimmel Cancer Center Network, discusses results from a study that assessed the corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer (mCRPC).
Read More
A Little STING May Enhance the Immune System Against Cancer
April 25th 2015Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.
Read More
'Using Common Sense' in Prostate Cancer Screening Debate
April 14th 2015The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press, but, Leonard G. Gomella, MD, says the decision to screen or not to screen boils down to “using common sense.â€
Read More
ADT May Impact Physical Function, Highlighting Need for Exercise
April 2nd 2015Shabbir M.H. Alibhai, MD, et al from the University Health Network in Toronto, Canada, found that impact from ADT on physical function persisted over 36 months, indicating ADT has lasting effects, which need to be addressed.
Read More
ADT With or Without Chemo Leads to Similar OS in Hormone-Sensitive Prostate Cancer
March 17th 2015Androgen deprivation therapy (ADT) with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, according to an updated analysis of a randomized trial.
Read More
AR-V7 in Prostate Cancer Cells Introduces Potential Therapeutic Target for CRPC
March 9th 2015A recent study showed that the androgen receptor (AR) splice variant AR-V7 activated full-length AR through an alternative biosynthesis pathway and increased citrate utilization through altered metabolic activities, which may partially explain its resistance to conventional androgen deprivation therapy (ADT).
Read More
Use With Caution: Active Surveillance in Patients With Intermediate-Risk Prostate Cancer
February 28th 2015The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients, according to results of a new study, the first to examine long-term outcomes of patients with low- versus intermediate-risk prostate cancer who have been managed with this conservative approach to care.
Read More
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
January 28th 2015Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.
Read More
Enzalutamide Improves PFS By Nearly 10 Months Over Bicalutamide in mCRPC
January 26th 2015Topline results from the phase II TERRAIN trial showed enzalutamide increased progression-free survival (PFS) by nearly 10 months compared with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Read More
Compliance in Metastatic Bone Disease Treatment Explored
December 17th 2014Bone-targeted agents may help to minimize complications associated with osseous metastases, such as skeletal-related events, but ongoing compliance and adherence to these therapies are important to ensure they provide the desired benefit.
Read More